Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.

Conclusions: This study revealed the promising observations that add-on treatment with SGLT2 inhibitors exerted significant renoprotective effects, culminating in improvements in annual decline in eGFR and urinary protein excretion in T2DM patients with CKD stages 3b-4, but did not significantly reduce HbA1c. Further prospective clinical trials are warranted to fully elucidate the effects of SGLT2 inhibitors on glycemic control and renal function in T2DM patients with moderate-to-severe renal impairment.
PMID: 30937117 [PubMed]

Source: Clin Med Res - March 31, 2019 Category: Research Authors: Sugiyama S, Jinnouchi H, Yoshida A, Hieshima K, Kurinami N, Jinnouchi K, Tanaka M, Suzuki T, Miyamoto F, Kajiwara K, Jinnouchi T Tags: J Clin Med Res Source Type: research